Department of Medicine

University of Pittsburgh

Julien J. Fourcade, PharmD, PhD

photo

Research Assistant Professor

Office: L1.3 Hillman Cancer Center
5117 Centre Ave
Pittsburgh, PA 15213
 
Phone:
Fax:
E-mail: fourcadejj@upmc.edu

Education
Pharm.D., University Paul Sabatier, Toulouse, France, 2003
Ph.D. in Oncology/Immunology, University of Aix-Marseille, France, 2012

Training
Postdoctoral Associate, University of Pittsburgh, 2006

Area of Specialization/Research Interest  
Cancer Immunology
Cancer Immunotherapy
Cancer vaccines
Tumor antigen-specific T cell biology
Tumor-induced immunosuppression
Immunologic checkpoints in cancer immunotherapies
 

Profile
Dr Fourcade's research activities are focused on the study of spontaneous and vaccine-induced T cell immune responses against melanoma and other solid tumors in cancer patients, and their interaction with other immune cell subsets involved in anti-tumor immunity. Dr Fourcade is also particularly involved in the study of the multiple mechanisms leading to tumor-induced immunosuppression in cancer patients, including the study of expression and functions of co-inhibitory receptors (ex: PD-1, BTLA, Tim-3) by tumor antigen (TA)-specific T cells and other immune cell subsets involved in anti-tumor immunity,the study of agents designed to target immunologic checkpoints and reverse tumor-induced TA-specific T cell dysfunction/exhaustion and the study of TA-specific Tregs.
His research also includes the identification of novel immunogenic antigens expressed by tumors and the clinical and immunological evaluation of new adjuvants that may help to optimize vaccines in cancer patients.

Recent Grants
Title: Role of the inhibitory receptor TIGIT in the regulation of CD4+ Tregs in patients with advanced melanoma
Role: Principal Investigator
Amount: $554,400
Funding Agency: US Department of Defense office of the Congressionally Directed Medical Research Programs
Start Year: 2015
End Year: 2018

Recent Peer-Reviewed Publications
Title: TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients
Author(s): Chauvin JM, Pagliano O, Fourcade J,, Sun Z, Wang H, Sander C,, Kirkwood JM, Chen TH, Maurer M, Korman AJ, Zarour HM
Year: 2015
Journal: J Clin Invest.
Volume: 2015 May 1;125(5)
Page(s): 2046-58
Title: PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines
Author(s): Fourcade J, Sun Z, Pagliano O, Chauvin JM, Wang H, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S,Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM
Year: 2014
Journal: Cancer Res.
Volume: 2014 Feb 15;74(4)
Page(s): 1045-55
Title: Strategies to reverse melanoma-induced T-cell dysfunction.
Author(s): Fourcade J, Zarour HM
Year: 2013
Journal: Clin Dermatol. 2013 May-Jun;31(3):251-6.
Volume:
Page(s):
Title: CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1.
Author(s): Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM
Year: 2012
Journal: Cancer Res. 2012 Feb 15;72(4):887-96
Volume:
Page(s):
Title: Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.
Author(s): Kudela P, Sun Z, Fourcade J, Janjic B, Kirkwood JM, Maillere B, Zarour HM
Year: 2011
Journal: J Immunol. 2011 Jan 1;186(1):312-22
Volume:
Page(s):
Title: Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire.
Author(s): Fourcade J, Sun Z, Kudela P, Janjic B, Kirkwood JM, El-Hafnawy T, Zarour HM
Year: 2010
Journal: J Immunol. 2010 Jun 15;184(12):6709-18.
Volume:
Page(s):
Title: Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
Author(s): Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM
Year: 2010
Journal: J Exp Med. 2010 Sep 27;207(10):2175-86.
Volume:
Page(s):
Title: PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
Author(s): Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM.
Year: 2009
Journal: J Immunol. 2009 May 1;182(9):5240-9.
Volume:
Page(s):
Title: Immunization with analogue peptide in combination with CpG and Montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
Author(s): Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM.
Year: 2008
Journal: J Immunother. 2008 Oct;31(8):781-91.
Volume:
Page(s):
Title: Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients.
Author(s): Kudela P, Janjic B, Fourcade J, Castelli F, Andrade P, Kirkwood JM, El-Hefnawy T, Amicosante M, Maillere B, Zarour HM.
Year: 2007
Journal: J Immunol.
Volume: 2007 Dec 1;179(11)
Page(s): 7932-40